1369430-77-2

Upstream product

• 1240304-76-0 methyl N-(2,2-dimethylbut-3-enoyl)-2-methylalaninate 
• 57690-96-7 2,2-dimethylbut-3-enoyl chloride 
• 1240304-75-9 u202fN-(2,2-dimethylbut-3-enoyl)-2-methylalanine 
• 1240304-62-4 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-{5-[(4-bromo-2-methylphenyl)methyl]-2-methoxy-4-(propan-2-yl)phenyl}-D-glucitol 
• 1240304-73-7 C₂₄H₃₁BrO₇ 
• 1240304-72-6 (1S)-1,5-anhydro-1-[5-bromo-2-methoxy-4-(propan-2-yl)phenyl]-2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucitol 
• 1240304-71-5 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[5-bromo-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol 
• 1240304-70-4 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol 
• 1240304-66-8 C₂₅H₃₄O₁₁ 
• 1359976-25-2 C₁₇H₂₆O₇ 
• 1240304-64-6 1-iodo-2-methoxy-4-(propan-2-yl)benzene 
• 618-45-1 3-isopropylhydroxybenzene 
• 10276-09-2 2,2-dimethyl-but-3-enoic acid 
• 1240304-54-4 1,5-dibromo-2-(methoxymethoxy)-4-(propan-2-yl)benzene 

Relevant academic research and scientific papers

4-Isopropyl-6-methoxyphenyl glucitol compound

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided:

4 -ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLTL INHIBITORS

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [Chem. 1] wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.